Spyre Therapeutics (SYRE) Amortization of Deferred Charges (2022 - 2023)
Spyre Therapeutics (SYRE) posted Amortization of Deferred Charges of $56000.0 for Q2 2023, down 65.85% on a QoQ basis from $164000.0 in Q1 2023, and down 42.27% year-over-year from $97000.0 in Q2 2022.
Spyre Therapeutics (SYRE) Amortization of Deferred Charges (2022 - 2023) Analysis & Trends
Spyre Therapeutics' Amortization of Deferred Charges history runs 2 years deep, the most recent figure standing at $56000.0 for Q2 2023.
- Quarterly Amortization of Deferred Charges fell 42.27% year-over-year to $56000.0 in Q2 2023, while the trailing twelve-month figure through Mar 2024 was $56000.0 (down 88.01% YoY) and the FY2023 annual result came in at $220000.0, down 44.58% from the prior year.
- Amortization of Deferred Charges was $56000.0 for Q2 2023 at Spyre Therapeutics, down from $164000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $164000.0 in Q1 2023 and bottomed at $56000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn |
| 10 | Spyre Therapeutics | 259.10 Mn | 259.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 56,000.00 |
| Jun 30, 2023 | 56,000.00 |
| Mar 31, 2023 | 164,000.00 |
| Mar 31, 2023 | 164,000.00 |
| Dec 31, 2022 | 105,000.00 |
| Dec 31, 2022 | 105,000.00 |
| Sep 30, 2022 | 101,000.00 |
| Sep 30, 2022 | 101,000.00 |
| Jun 30, 2022 | 97,000.00 |
| Jun 30, 2022 | 97,000.00 |
| Mar 31, 2022 | 94,000.00 |
| Mar 31, 2022 | 94,000.00 |